Updates

24th August, 2026 BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (East), Mumbai – 400 051 BSE scrip code: 543635 NSE symbol: PPLPHARMA Dear Sir / Madam, Sub: Sustainability Report of Piramal Pharma Limited (‘the Company’) for the financial year 2025-26 Please find enclosed herewith Sustainability Report of the Company for the financial year 2025-26. The said information is also available on the website of the Company at https://www.piramalpharma.com/sustainability/index. Request you to please take the above on record. Thank you. Yours truly, For Piramal Pharma Limited Maneesh Sharma Company Secretary & Compliance Officer Encl: a/a Piramal Pharma Limited CIN: L24297MH2020PLC338592 Registered Office: Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070, Maharashtra, India Tel No. +91 22 3802 3000 / 4000; Email Id: shareholders.ppl@piramal.com www.piramalpharma.com Piramal Pharma Limited Sustainability Report 2025-26 Advancing Innova(cid:31)on, Leveraging Sustainability. What’s Inside Key Sustainability Pillars Overview of This Report1 01 Overview of This Report 20 52 At Piramal Pharma Limited (PPL), Reporting Frameworks and Accountability 02 A dvancing Innovation, P P sustainability shapes how we operate, Leveraging Sustainability. how we make decisions and how we stay Standards PPL’s sustainability disclosures are 04 Awards and Accolades accountable to those who place their This Sustainability Report has been aligned with applicable regulatory 05 Notable Achievements Business Resilience Quality and Excellence trust in us. It is reflected in the discipline prepared in accordance with the Global requirements and stakeholder 06 Leadership Message with which we follow through on our Reporting Initiative (GRI) Universal expectations. All disclosures undergo 08 Piramal Pharma in Focus commitments and in the clarity with Standards 2021. It addresses all nine internal review and validation by cross which we communicate our progress. disclosure requirements under GRI 1: functional teams, with appropriate 10 Global Presence Against this backdrop, we present our Foundation, GRI 2: General Disclosures management oversight to ensure 12 Business Performance Sustainability Report for FY2026, covering and GRI 3: Material Topics. accuracy, completeness and consistency. 14 Business Strategy non-financial performance for the period Our disclosures are also aligned 16 Stakeholder Engagement from April 1, 2025, to March 31, 2026. Contact3 with the United Nations Sustainable 18 Double Materiality Assessment The past year represented an important Development Goals (UN SDGs), We value transparent and continuous phase in PPL’s sustainability journey. It reflecting our commitment to engagement with our stakeholders. Business Resilience was marked by visible outcomes and also responsible business practices that are Queries, comments or feedback on 22 Corporate Governance by stronger systems, sharper priorities relevant in a global context. this report may be directed to our 30 B usiness Ethics and and a more embedded approach to sustainability spokesperson at Compliance responsible growth. Across operations, Reporting Period, Scope and ganesh.tripathy@piramal.com 76 104 governance and community engagement, or through 34 Enterprise Risk Management Boundary2 sustainability considerations increasingly ppl.sustainability@piramal.com. 40 D ata Protection and informed the way we planned, The information disclosed in this report Cyber Security invested and executed. relates to FY2026, covering the period Forward-Looking Statement 42 Responsible Supply Chain Responsible Operations Stakeholder Centricity from April 1, 2025, to March 31, 2026. This report brings together our actions The reporting scope includes three This report includes forward-looking and outcomes across the Environment, Quality and Excellence business units: Piramal Pharma Solutions statements relating to the Company’s Social and Governance pillars. During the 54 Quality and Excellence (PPS), Piramal Critical Care (PCC) and strategies, initiatives, targets and year, our focus areas included accelerating Piramal Consumer Healthcare (PCH). expected performance. Such statements 62 Technology and Automation the shift towards energy-efficient are based on current assumptions and 68 Operational Excellence technologies, increasing the share of These businesses operate development estimates and are subject to known renewable energy in our operations and manufacturing facilities across India, and unknown risks and uncertainties. Responsible Operations and strengthening circular practices the United Kingdom and North America. Terms such as “will”, “believes”, 78 Climate Change through improved waste segregation and The scope and boundary of the report “estimates”, “aims”, “anticipates” and resource management. We advanced are consistent with PPL’s consolidated “plans” are intended to identify forward 82 Energy Management water conservation efforts and expanded annual financial statements. looking intent. 94 W ater Stewardship and community programmes with a sustained The Company is headquartered Waste Management emphasis on education and skill in Mumbai, India. Actual results may differ materially. development. At our sites, health, safety The Company does not undertake any Stakeholder Centricity and employee well-being stayed central Materiality obligation to update forward-looking 106 Our People and Culture to how work is designed and delivered. statements considering future events or Reporting Suite 2025-26 The set of material topics reported new information. 122 Occupational Health We saw renewed attention on governance this year is consistent with previous and Safety foundations during the year. We reporting periods, unless stated External Assurance4 138 Customer Centricity strengthened internal policies to further otherwise. These topics were identified 142 Community Development embed ethical business practices and through structured stakeholder Key sustainability disclosures in this undertook structured risk assessments engagement and a rigorous materiality report have been independently assured Annexures to reinforce transparency, oversight and assessment process. to enhance credibility and reliability. The To know more about us, explore decision-making across the organisation. external assurance has been carried out 152 Annexure 1: GRI Index piramalpharma.com The report is designed to communicate by DNV Business Assurance India Pvt 157 Annexure 2: Stakeholder S Ec lea vli an tig n I gn n So civ ea nti co en .. Together, these efforts represent our PPL’s key sustainability priorities, long Ltd. The assurance statement is provided steady progress in translating intent Engagement and Double term objectives and targets, progress as an annexure to this report. into action. This report is intended to Materiality Assessment achieved during the year and the offer stakeholders a clear, coherent outcomes generated for relevant 161 A nnexure 3: Sustainability Piramal Pharma Limited Restatements5 Annual Report 2025-26 view of PPL’s sustainability priorities, the stakeholder groups. KPI Status FY2026 choices we are making and the impact Annual Report 2025-26 There were no material restatements 166 A nnexure 4: GHG Verification we are creating. during the reporting period. Statement 170 A nnexure 5: Assurance Statement 12-1 | 22-2 | 32-3 | 42-5 | 52-4 Piramal Pharma is entering its next phase of growth with a sharper focus on innovation that addresses critical healthcare needs. We are advancing scientific solutions with precision and care while embedding sustainability into the way we operate, making our systems smarter, more resilient and forward-looking. Every step forward is guided by a commitment to scale responsibly, reduce our environmental footprint, enhance o [Showing first 8,000 characters — download PDF for full document]